Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Stilgenbauer

Showing results (221-230 of 466) with videos related to

Pageof 47
Sort By:
Leukemia|August 21, 2019
The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximabKarl-Anton Kreuzer, Richard R Furman, Stephan Stilgenbauer, et al.
Cancer Research|November 17, 2006
Molecular imaging of proliferation in malignant lymphomaAndreas K Buck, Martin Bommer, Stephan Stilgenbauer, et al.
European Journal of Haematology|November 19, 2016
Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trialOthman Al-Sawaf, Kirsten Fischer, Carmen D Herling, et al.
Haematologica|March 18, 2021
Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patientsJohannes Bloehdorn, Julia Krzykalla, Karlheinz Holzmann, et al.
Cancer|March 21, 2013
Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemiaGeorg Hopfinger, Raymonde Busch, Natali Pflug, et al.
Blood|October 13, 2005
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemiaBarbara F Eichhorst, Raymonde Busch, Georg Hopfinger, et al.
Haematologica|November 2, 2020
Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG)Sonia Jaramillo, Andreas Agathangelidis, Christof Schneider, et al.
Cellular & Molecular Biology Letters|May 7, 2026
CRISPR and compound screens in a novel ex vivo tissue model identify DDR1 and ETA as regulators of cancer cell invasionJunnan Liu, Wencheng Jiang, Xue Wang, et al.
Cancer Medicine|December 1, 2023
Regional outcome disparities in German head and neck cancer patients: Shorter survival in Eastern GermanyJulius M Vahl, Gabriele Nagel, Tsima Abou Kors, et al.
Blood|January 29, 2020
High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemiaOthman Al-Sawaf, Esther Lilienweiss, Jasmin Bahlo, et al.
Pageof 47

Showing results (221-230 of 466) with videos related to

Sort By:
Pageof 47
Leukemia|August 21, 2019
The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximabKarl-Anton Kreuzer, Richard R Furman, Stephan Stilgenbauer, et al.
Cancer Research|November 17, 2006
Molecular imaging of proliferation in malignant lymphomaAndreas K Buck, Martin Bommer, Stephan Stilgenbauer, et al.
European Journal of Haematology|November 19, 2016
Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trialOthman Al-Sawaf, Kirsten Fischer, Carmen D Herling, et al.
Haematologica|March 18, 2021
Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patientsJohannes Bloehdorn, Julia Krzykalla, Karlheinz Holzmann, et al.
Cancer|March 21, 2013
Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemiaGeorg Hopfinger, Raymonde Busch, Natali Pflug, et al.
Blood|October 13, 2005
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemiaBarbara F Eichhorst, Raymonde Busch, Georg Hopfinger, et al.
Haematologica|November 2, 2020
Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG)Sonia Jaramillo, Andreas Agathangelidis, Christof Schneider, et al.
Cellular & Molecular Biology Letters|May 7, 2026
CRISPR and compound screens in a novel ex vivo tissue model identify DDR1 and ETA as regulators of cancer cell invasionJunnan Liu, Wencheng Jiang, Xue Wang, et al.
Cancer Medicine|December 1, 2023
Regional outcome disparities in German head and neck cancer patients: Shorter survival in Eastern GermanyJulius M Vahl, Gabriele Nagel, Tsima Abou Kors, et al.
Blood|January 29, 2020
High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemiaOthman Al-Sawaf, Esther Lilienweiss, Jasmin Bahlo, et al.
Pageof 47